for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celldex Therapeutics, Inc.

CLDX.O

Latest Trade

2.27USD

Change

0.00(0.00%)

Volume

79,257

Today's Range

2.25

 - 

2.36

52 Week Range

2.01

 - 

11.62

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.27
Open
2.32
Volume
79,257
3M AVG Volume
2.92
Today's High
2.36
Today's Low
2.25
52 Week High
11.62
52 Week Low
2.01
Shares Out (MIL)
15.90
Market Cap (MIL)
36.62
Forward P/E
-0.59
Dividend (Yield %)
--

Next Event

Q4 2019 Celldex Therapeutics Inc Earnings Release

Latest Developments

More

Celldex Provides Corporate Update And Reports Third Quarter 2019 Results

Celldex Therapeutics Says Q2 Loss Per Share $0.84

Celldex Q1 Loss Per Share $1.40

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Industry

Biotechnology & Drugs

Contact Info

53 Frontage Rd Ste 220

+1.908.2007500

http://www.celldextherapeutics.com

Executive Leadership

Larry Ellberger

Independent Chairman of the Board

Anthony S. Marucci

President, Chief Executive Officer, Director

Sam Martin

Chief Financial Officer, Senior Vice President, Secretary

Tibor Keler

Executive Vice President and Chief Scientific Officer

Sarah Cavanaugh

Senior Vice President - Corporate Affairs and Administration

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-19.050

2017

-10.800

2018

-14.480

2019(E)

-3.980
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.23
Price To Book (MRQ)
0.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-36.73
Return on Equity (TTM)
-33.21

Latest News

Latest News

BRIEF-Novartis Receives Health Canada Approval Of Its Car-T Cell Therapy, Kymriah I

* NOVARTIS RECEIVES HEALTH CANADA APPROVAL OF ITS CAR-T CELL THERAPY, KYMRIAH™ (TISAGENLECLEUCEL)I

BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS

BRIEF-Celldex Therapeutics Approves Workforce Reduction

* CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics promotes Sam Martin as CFO

* Celldex Therapeutics announces additions to the board of directors and senior management team

BRIEF-Celldex presents data from phase 2 study of glembatumumab vedotin

* Celldex presents promising overall survival data from phase 2 study of single-agent glembatumumab vedotin in patients with checkpoint-refractory metastatic melanoma

BRIEF-Celldex reports Q1 loss per share $0.28

* Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016

* COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING Source text (http://bit.ly/2lwtvZF) Further company coverage:

BRIEF-Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock

* Files for offering of up to 18.4 million shares of common stock by the selling stockholders Source text : (http://bit.ly/2kpoaTY) Further company coverage:

BRIEF-Celldex reports Q3 loss per share $0.29

* Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up